WOBURN, Mass. , Sept. 06, 2018 (GLOBE NEWSWIRE) — Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immunotherapies derived from its Immulytic™ platform, today announced the U.S. Food and Drug Administration ( FDA ) has accepted the Company’s investigational new